We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Opportunity Still Exists for Diagnostic Companies in India

By LabMedica International staff writers
Posted on 28 Oct 2009
Diagnostic companies seeking new growth opportunities in a recessionary economy may want to consider the US$350 million Indian in vitro diagnostics (IVD) market, according to a new market report. More...
In spite of poor economic news elsewhere, demographics in India are fueling a robust private hospital industry, which in turn is driving testing markets.

While India's growth rate is not in the double digits as predicted earlier this decade, quarterly 2009 numbers have been positive and the IMF projects India's growth rate to be 5.8% this year--good news in a time when most developed countries are showing negative growth, according to from healthcare market research publisher Kalorama Information (New York, NY, USA) and McEvoy and Farmer (Seattle, WA, USA). India's 1.14 billion population is increasingly migrating to urban centers where there is better ability to deliver healthcare. A middle class of approximately 200 million has emerged around the cities of Delhi, Mumbai, and the southern corridor of Hyderabad and Chennai, and these urban middle-class consumers are demanding quality healthcare services. Private hospitals, insurance companies, and laboratories have sprung up to fill the fast-rising demand.

"Growth in the Indian IVD market is fueled by private healthcare dollars,” said Bruce Carlson, publisher of Kalorama Information. "Private hospitals are expanding through acquisitions and the building of new facilities, and hospitals will drive testing for the increased patient population.”

While the Indian government spends about 1% of gross domestic product (GDP) on healthcare, or $4 per person, private healthcare spending is four to five times that amount. Although only a small percentage of Indians are covered by health insurance, private insurance plans are expanding, facilitating the use of medical services without payment up-front. Private laboratory chains are thriving. SRL Ranbaxy (Haryana, India) has significant processing labs in Mumbai, Delhi, and other major cities and collects samples from 350 towns countrywide. Dr. Lal Path Labs (Gurgaon, India) has 27 labs and collects from 250 towns. Although foreign companies have not entered the private lab market in a significant way here, Quest recently opened a large facility. Siemens Healthcare Diagnostics, Inc. (Erlangen, Germany), Abbott Labs (Abbott Park, IL, USA), and Beckman Coulter (Fullerton, CA, USA) are among the other companies with significant offices in India, and other foreign companies are expected. Kalorama Information, working closely with the IVD market research firm McEvoy and Farmer, projects the Indian IVD market will grow at 15% per year as a result of this private healthcare expansion.

Kalorama Information supplies independent market research in the life sciences, as well as a full range of custom research services.

McEvoy & Farmer is a partnership between Carl McEvoy and Michael Farmer, both experienced specialists in the study of in vitro diagnostic (IVD) markets

Related Links:
Kalorama Information
McEvoy and Farmer


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.